SOLENO THERAPEUTICS INC - 8-K Filing
On May 18, 2026, Soleno Therapeutics completed its merger with Neurocrine Biosciences under a $53.00 per share cash tender offer that achieved approximately 88.9% shareholder participation. The company terminated its loan agreement and employee stock purchase plan as part of the transaction, became a wholly owned subsidiary of Neurocrine, and notified Nasdaq to delist its shares. (Items: 1.02 Termination of a Material Definitive Agreement On May 18, 2026, in connection with the Merger, the Company, as borrower, terminated the Loan, 2.01 Item 3, 3.03 Material Modification to Rights of Security Holders The information set forth in the Introductory Note and Items 2, 5.01 Item 5)
Tickers: $SLNO